Literature DB >> 22982575

Hereditary conjugated hyperbilirubinaemia: 37 years later.

Daniel Dhumeaux1, Serge Erlinger.   

Abstract

Bilirubin, a breakdown product of heme, is normally glucuronidated and excreted by the liver into bile. Failure of this system can lead to a buildup of conjugated bilirubin in the blood, resulting in jaundice. The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3. These important detoxification-limiting proteins mediate uptake and clearance of countless drugs and drug conjugates across the sinusoidal hepatocyte membrane. OATP1B1 polymorphisms have previously been linked to drug hypersensitivities. Using mice deficient in Oatp1a/1b and in the multispecific sinusoidal export pump Abcc3, we found that Abcc3 secretes bilirubin conjugates into the blood, while Oatp1a/1b transporters mediate their hepatic re uptake. Transgenic expression of human OATP1B1 or OATP1B3 restored the function of this detoxification-enhancing liver-blood shuttle in Oatp1a/1b-deficient mice. Within liver lobules, this shuttle may allow flexible transfer of bilirubin conjugates (and probably also drug conjugates) formed in upstream hepatocytes to downstream hepatocytes, thereby preventing local saturation of further detoxification processes and hepatocyte toxic injury. Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.

Entities:  

Year:  2012        PMID: 22982575     DOI: 10.1016/j.jhep.2012.08.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

Review 1.  SLC transporters as therapeutic targets: emerging opportunities.

Authors:  Lawrence Lin; Sook Wah Yee; Richard B Kim; Kathleen M Giacomini
Journal:  Nat Rev Drug Discov       Date:  2015-06-26       Impact factor: 84.694

2.  Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake.

Authors:  Vusumuzi N Hove; Kenneth Anderson; Elizabeth R Hayden; Kyle Z Pasquariello; Alice A Gibson; Shichen Shen; Jun Qu; Yan Jin; Jeffrey C Miecznikowski; Shuiying Hu; Jason A Sprowl
Journal:  Mol Pharmacol       Date:  2022-04-05       Impact factor: 4.054

3.  Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease.

Authors:  Xinrun Ma; Xuyang Shang; Xuan Qin; Jian Lu; Mingyao Liu; Xin Wang
Journal:  Acta Pharm Sin B       Date:  2019-11-14       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.